Optimizing Adjuvant Abemaciclib: Insights From the TRADE Study on Dose Escalation and Tolerability

In this first installment, Dr Mayer discusses the results of the adjuvant TRADE study and how it was successful in identifying a dose-escalation strategy for abemaciclib that allowed a significant number of patients to reach and maintain the target with very few patients discontinuing therapy.